saterinone has been researched along with Chronic Disease in 1 studies
*Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumann, G; Eichner, E; Iven, H; Kieback, AG; Ruckdeschel, W; Stolzenburg, K | 1 |
1 other study(ies) available for saterinone and Chronic Disease
| Article | Year |
|---|---|
Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Blood Platelets; Blood Pressure; Chronic Disease; Creatine Kinase; Creatinine; Cyclic Nucleotide Phosphodiesterases, Type 3; Diastole; Heart Atria; Heart Failure; Heart Rate; Humans; Infusions, Intravenous; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Pyridones; Statistics as Topic; Stroke Volume; Systole; Time Factors; Treatment Outcome; Vascular Resistance | 2003 |